Vicore Pharma AB

ALMEE

Providing of on-line training and continuing education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; Educational services, namely, providing continuing professional education courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from depression and anxiety related to Pulmonary Fibrosis and for medical personnel specialized on the treatment of depression and anxiety;The mark consists of of a green outline of overlapping, rounded geometric figures all connected at the bottom above ALMEE in stylized green font. The color white represents background, outlining, shading, and/or transparent areas and is not part of the mark.;Downloadable computer software with medical information and content for facilitating the provision of medical advice in the field of depression and anxiety related to Pulmonary Fibrosis; downloadable computer software programs for the administration of scientific content in the nature of analysis of medical data; downloadable computer programs, in particular interactive downloadable medical software for treating patients suffering from depression and anxiety related to Pulmonary Fibrosis and for supporting medical personnel for the purpose of treating depression and anxiety; downloadable computer software program which is designed to assist patients in reducing and coping with the symptoms of depression and anxiety related to Pulmonary Fibrosis as well as in improving their wellbeing and social occupational functioning and to support health care professionals involved in the treatment of patients with depression and anxiety related to Pulmonary Fibrosis by facilitating the provision of medical advice; downloadable computer application software for websites, mobile telephones and mobile devices, namely, software for treating patients suffering from depression and anxiety related to Pulmonary Fibrosis; downloadable printable educational materials featuring therapeutic medical and counselling content, in the nature of information, forms, instructions, charts, studies, data and related coaching and advice in the field of depression and anxiety related to Pulmonary Fibrosis, treatment of depression and anxiety related to Pulmonary Fibrosis, and related health and wellness; downloadable electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of depression and anxiety related to Pulmonary Fibrosis;The color(s) green is/are claimed as a feature of the mark.;Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, depression and anxiety related to Pulmonary Fibrosis; Providing medical information, namely, computer-based interactive medical support services in the nature of providing online medical advice for assisting with treatment of patients suffering from depression and anxiety related to Pulmonary Fibrosis and their families;Providing a website featuring digital therapeutic technology that enables users to access resources for treating depression and anxiety related to Pulmonary Fibrosis; providing an online digital therapeutic platform in the nature of providing on-line non-downloadable software for providing behavioural health services, namely, coaching, counselling, advice in the field of depression and anxiety related to Pulmonary Fibrosis; conducting medical and scientific and technological research in the field of depression and anxiety related to Pulmonary Fibrosis; Scientific and technological services, namely, conducting technological research and design of digital therapeutics for computer-based interactive and online psychological intervention and counselling in the field of depression and anxiety related to Pulmonary Fibrosis; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of depression and anxiety related to Pulmonary Fibrosis and the treatment of depression and anxiety related to Pulmonary Fibrosis;

SPIROXIS

Pharmaceuticals and medical preparations for human use, namely, prescription drugs, namely, pills, tablets, capsules, caplets, and liquid drops sachets for the treatment of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases; pharmaceutical preparations for use within the fields of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases; pharmaceutical preparations for treating and preventing pulmonary fibrosis, namely, idiopathic pulmonary fibrosis; pharmaceutical preparations for use in treating diffuse systemic sclerosis with lung manifestations; pharmaceutical preparations for treating infectious lung diseases; pharmaceutical preparations for treatment and prevention of covid-19;

VICEOLIS

Pharmaceuticals and medical preparations for human use; pharmaceutical preparations within the fields of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases; pharmaceutical preparations for pulmonary fibrosis, namely, ipf; pharmaceutical preparations for diffuse systemic sclerosis (lung manifestations); pharmaceutical preparations for infectious lung diseases; pharmaceutical preparations for covid-19;

VICORE

Pharmaceuticals and medical preparations for human use, namely, prescription drugs, namely, pills, tablets, capsules, caplets, and liquid drops sachets for the treatment fibrotic lung disease;Medical and pharmacological research services; medical and pharmacological research services within the fields of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases; medical and pharmacological research services within the fields of pulmonary fibrosis, namely, ipf, pulmonary sarcoidosis and diffuse systemic sclerosis, in particular in the field of lung manifestations; pharmaceutical research and development; scientific research and development; medical research laboratory services; medical research; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical drug development services; pharmaceutical drug delivery system development services; pharmaceutical drug development services, namely, preparation and/or formulation of pharmaceuticals; medical product testing services; clinical research and professional expertise relating thereto in the nature of professional expertise in the field of clinical research for others; all of the foregoing services for the treatment of fibrotic lung disease;

VICORE ALMEE

Providing of on-line training and continuing education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; Educational services, namely, providing continuing professional education courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from depression and anxiety related to Pulmonary Fibrosis and for medical personnel specialized on the treatment of depression and anxiety;Downloadable computer software with medical information and content for facilitating the provision of medical advice in the field of depression and anxiety related to Pulmonary Fibrosis; downloadable computer software programs for the administration of scientific content in the nature of analysis of medical data; downloadable computer programs, in particular interactive downloadable medical software for treating patients suffering from depression and anxiety related to Pulmonary Fibrosis; downloadable computer software program which is designed to assist patients in reducing and coping with the symptoms of depression and anxiety related to Pulmonary Fibrosis as well as in improving their wellbeing and social occupational functioning and to support health care professionals involved in the treatment of patients with depression and anxiety related to Pulmonary Fibrosis by facilitating the provision of medical advice; downloadable computer application software for websites, mobile telephones and mobile devices, namely, software for treating patients suffering from depression and anxiety related to Pulmonary Fibrosis; Downloadable printable educational materials featuring therapeutic medical and counseling content, in the nature of information, forms, instructions, charts, studies, data and related coaching and advice in the field of depression and anxiety related to Pulmonary Fibrosis, treatment of depression and anxiety related to Pulmonary Fibrosis, and related health and wellness; Downloadable electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of depression and anxiety related to Pulmonary Fibrosis;Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, depression and anxiety related to Pulmonary Fibrosis; Providing medical information, namely, computer-based interactive medical support services, in the nature of providing online medical advice for assisting with treatment of patients suffering from depression and anxiety related to Pulmonary Fibrosis and their families; Medical treatment of depression and anxiety by medical personnel;Providing a website featuring digital therapeutic technology that enables users to access resources for treating depression and anxiety related to Pulmonary Fibrosis; providing an online digital therapeutic platform in the nature of providing on-line non-downloadable software for providing behavioral health services, namely, coaching, counseling, advice in the field of depression and anxiety related to Pulmonary Fibrosis; conducting medical and scientific and technological research in the field of depression and anxiety related to Pulmonary Fibrosis; Scientific and technological services, namely, conducting technological research and design of digital therapeutics for computer-based interactive and online psychological intervention and counseling in the field of depression and anxiety related to Pulmonary Fibrosis; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of depression and anxiety related to Pulmonary Fibrosis and the treatment of depression and anxiety related to Pulmonary Fibrosis;